林业发展局宣布结束Wegovy和Ozempic的短缺;复合药店必须停止替代药。 FDA announces end to shortage of Wegovy and Ozempic; compounding pharmacies must stop substitutes.

美国食品和药物管理局宣布全国范围内新诺迪斯克减肥和糖尿病药物Wegovy和Ozempic的短缺已经结束. The FDA has announced the end of the nationwide shortage of Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic. 该公司增加了产量,并投资数十亿美元以满足需求。 The company increased production and invested billions to meet demand. 复合药店一直在生产更廉价的替代品,必须在60至90天内停止生产这些替代品。 Compounding pharmacies, which have been making cheaper alternatives, must stop producing these substitutes within 60 to 90 days.